Alkem Laboratories Limited (NSE:ALKEM)
India · Delayed Price · Currency is INR 5,368.00
-81.50 (-1.50%)
Aug 14, 2026, 3:15 PM IST
Alkem Laboratories Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 150,813 | 147,123 | 129,645 | 126,676 | 115,993 | 106,342 | |
Revenue Growth | 13.36% | 13.48% | 2.34% | 9.21% | 9.07% | 19.96% |
Cost of Revenue | 53,081 | 52,780 | 49,255 | 50,642 | 50,207 | 42,806 |
Gross Profit | 97,732 | 94,343 | 80,391 | 76,034 | 65,785 | 63,536 |
Selling, General & Admin | 39,531 | 38,374 | 32,422 | 30,324 | 29,726 | 25,769 |
Other Operating Expenses | 28,096 | 26,134 | 22,879 | 23,041 | 19,760 | 17,305 |
Operating Expenses | 71,572 | 68,328 | 58,873 | 56,359 | 52,589 | 46,103 |
Operating Income | 26,159 | 26,014 | 21,518 | 19,676 | 13,196 | 17,432 |
Interest Expense | -1,574 | -1,406 | -1,048 | -970.8 | -809.2 | -308.9 |
Interest & Investment Income | 3,916 | 3,916 | 3,588 | 2,758 | 1,711 | 1,227 |
Earnings From Equity Investments | -20.7 | -19.7 | -6.2 | - | - | - |
Currency Exchange Gain (Loss) | 849 | 849 | 380 | -335.1 | -188.6 | -16.5 |
Other Non Operating Income (Expenses) | 448.1 | 285.5 | 239.6 | 179.2 | -12.8 | -24.2 |
EBT Excluding Unusual Items | 29,778 | 29,640 | 24,671 | 21,307 | 13,897 | 18,309 |
Gain (Loss) on Sale of Investments | 537.8 | 537.8 | 528.9 | 151.7 | 308.6 | 114.5 |
Gain (Loss) on Sale of Assets | 15 | 15 | 46 | -31.8 | -123.6 | 19.7 |
Asset Writedown | -747 | -747 | -137.3 | -576.5 | -1,051 | -11.2 |
Other Unusual Items | -885.8 | -756.5 | 155.1 | -618.6 | 17.4 | 10.5 |
Pretax Income | 28,698 | 28,689 | 25,264 | 20,231 | 13,048 | 18,443 |
Income Tax Expense | 6,656 | 5,178 | 3,110 | 2,117 | 2,980 | 1,640 |
Earnings From Continuing Operations | 22,042 | 23,512 | 22,154 | 18,115 | 10,068 | 16,803 |
Minority Interest in Earnings | -467.3 | -493.6 | -499 | -156.9 | -226.4 | -347 |
Net Income | 21,575 | 23,018 | 21,655 | 17,958 | 9,842 | 16,456 |
Net Income to Common | 21,575 | 23,018 | 21,655 | 17,958 | 9,842 | 16,456 |
Net Income Growth | -5.56% | 6.30% | 20.59% | 82.47% | -40.20% | 3.82% |
Shares Outstanding (Basic) | 120 | 120 | 120 | 120 | 120 | 120 |
Shares Outstanding (Diluted) | 120 | 120 | 120 | 120 | 120 | 120 |
Shares Change | -0.00% | - | - | - | - | - |
EPS (Basic) | 180.45 | 192.51 | 181.11 | 150.19 | 82.31 | 137.63 |
EPS (Diluted) | 180.45 | 192.51 | 181.11 | 150.19 | 82.31 | 137.63 |
EPS Growth | -5.56% | 6.30% | 20.59% | 82.47% | -40.20% | 3.82% |
Free Cash Flow | - | 13,458 | 12,372 | 16,888 | 14,496 | 7,721 |
Free Cash Flow Per Share | - | 112.56 | 103.48 | 141.24 | 121.24 | 64.58 |
Dividend Per Share | 53.000 | 53.000 | 45.000 | 40.000 | 25.000 | 34.000 |
Dividend Growth | 17.78% | 17.78% | 12.50% | 60.00% | -26.47% | 13.33% |
Gross Margin | 64.80% | 64.13% | 62.01% | 60.02% | 56.72% | 59.75% |
Operating Margin | 17.34% | 17.68% | 16.60% | 15.53% | 11.38% | 16.39% |
Profit Margin | 14.31% | 15.65% | 16.70% | 14.18% | 8.48% | 15.47% |
Free Cash Flow Margin | - | 9.15% | 9.54% | 13.33% | 12.50% | 7.26% |
EBITDA | 29,264 | 29,118 | 24,619 | 22,268 | 15,893 | 20,122 |
EBITDA Margin | 19.40% | 19.79% | 18.99% | 17.58% | 13.70% | 18.92% |
D&A For EBITDA | 3,105 | 3,104 | 3,101 | 2,592 | 2,697 | 2,690 |
EBIT | 26,159 | 26,014 | 21,518 | 19,676 | 13,196 | 17,432 |
EBIT Margin | 17.34% | 17.68% | 16.60% | 15.53% | 11.38% | 16.39% |
Effective Tax Rate | 23.19% | 18.05% | 12.31% | 10.46% | 22.84% | 8.89% |
Revenue as Reported | 156,809 | 152,956 | 134,583 | 129,784 | 118,153 | 107,968 |